Scientists believe that although faecal transplants have gained attention recently and have shown promise in everything from COVID-19 therapies to anti-aging studies in animals, we are still just at the very beginning of this field.
The procedure involves transferring faecal microbiota from a healthy adult to the other, is typically used to treat diseases like Clostridioides difficile infection (CDI) and inflammatory bowel disease (IBD) in humans, but experts believe it has the potential to be applied to a much wider range of illnesses.
Additionally, we could avoid problems that occasionally arise because of incompatibility problems between senders and receivers in heterologous transplants involving two people by developing a system to produce autologous faecal transplants (FMT), in which the donor and the receiver are the same individual.
Stool banking for autologous FMT is conceptually comparable to parents who store their child’s cord blood for potential use in the future.
Additionally, there is already poo banking; the first was a charity stoma bank called OpenBiome that started operations in Somerville, Massachusetts, in 2012.
Since then, a number of such facilities have popped up all over the world, albeit the majority seem to primarily be keeping stool samples for upcoming heterologous FMTs rather than for autologous transplants; the two methods aren’t necessarily exclusive.
In theory, autologous FMT may be utilised to rejuvenate the microbiome using the same host screening and sample collecting process.
According to research Asthma, multiple sclerosis, inflammatory bowel disease, diabetes, obesity, heart disease, and even ageing may all be able to be treated using autologous FMTs.
For more such interesting content subscribe to Transformative.today